News & Media

Events
ProHearings Investor Meeting

The presentation will be streamed live at www.prohearings.com

Read more
Events
Interim Report January - September 2019

Read more
Events
Redeye Life Science Day

Read more
Events
BIO Europe 2019

Read more
Press release
Medivir presents MIV-818 data at AACR-NCI-EORTC in Boston

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled “MIV-818 stimulates an anti-tumor immune response in...

Read more
Press release
US National Cancer Institute initiates phase I study of treatment of head and neck cancer patients with Medivir’s birinapant and radiation therapy

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2019

April – JuneSignificant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The...

Read more
Press release
Selective effect signal on liver cancer tissue in phase Ia study with MIV-818

Stockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...

Read more
Press release
Medivir to present at the 2019 BIO International Convention

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...

Read more
Press release
New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release
Medivir to present at the Redeye Pre-ASCO Seminar on May 28

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....

Read more
Press release
New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more